Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record, with a small difference in title or year; 31 of the 31 references it cites were found in a registry or an index.

Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes

Knopp, Robert H., d’Emden, Michael, Smilde, Johan G., Pocock, Stuart J., on behalf of the ASPEN Study Group · 2006 · Diabetes Care

Abstract

OBJECTIVE—Cardiovascular disease (CVD) risk is increased in type 2 diabetes. The purpose of this study was to assess the effect of 10 mg of atorvastatin versus placebo on CVD prevention in subjects with type 2 diabetes and LDL cholesterol levels below contemporary guideline targets. RESEARCH DESIGN AND METHODS—Subjects were randomly assigned to receive 10 mg of atorvastatin or placebo in a 4-year, double-blind, parallel-group study. The composite primary end point comprised cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, recanalization, coronary artery bypass surgery, resuscitated cardiac arrest, and worsening or unstable angina requiring hospitalization. RESULTS—A total of 2,410 subjects with type 2 diabetes were randomized. Mean LDL cholesterol reduction in the atorvastatin group over 4 years was 29% versus placebo (P < 0.0001). When we compared atorvastatin versus placebo, composite primary end point rates were 13.7 and 15.0%, respectively (hazard ratio 0.90 [95% CI 0.73–1.12]). In the subset of 1,905 subjects without prior myocardial infarction or interventional procedure, 10.4% of atorvastatin- and 10.8% of placebo-treated subjects experienced a primary end point (0.97 [0.74–1.28]). In the 505 subjects with prior myocardial infarction or interventional procedure, 26.2% of atorvastatin- and 30.8% of placebo-treated subjects experienced a primary end point (0.82 [0.59–1.15]). Relative risk reductions in fatal and nonfatal myocardial infarction were 27% overall (P = 0.10) and 19% (P = 0.41) and 36% (P = 0.11) for subjects without and with prior myocardial infarction or interventional procedure, respectively. CONCLUSIONS—Composite end point reductions were not statistically significant. This result may relate to the overall study design, the types of subjects recruited, the nature of the primary end point, and the protocol changes required because of changing treatment guidelines. For these reasons, the results of the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) did not confirm the benefit of therapy but do not detract from the imperative that the majority of diabetic patients are at risk of coronary heart disease and deserve LDL cholesterol lowering to the currently recommended targets.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc05-2415

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

See all 550

Metadata

Authors
Knopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group
Affiliations
  • University of Washington (US)
  • Department of Medicine, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia
  • Refaja Ziekenhuis (NL)
  • London School of Hygiene & Tropical Medicine (GB)
Venue
Diabetes Care
Published
2006-07-01
Volume
29
Issue
7
Pages
1478-1485
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2126563293
Cited by
550
References
31
Citations by year
2026: 9 · 2025: 6 · 2024: 22 · 2023: 19 · 2022: 25 · 2021: 19 · 2020: 26 · 2019: 23 · 2018: 24 · 2017: 19 · 2016: 26 · 2015: 35 · 2014: 28 · 2013: 37 · 2012: 31
FWCI
39.66
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Keywords
type 2 diabetes, cardiovascular disease prevention, LDL cholesterol, statins, cardiovascular mortality, myocardial infarction, stroke, coronary artery disease, primary prevention, secondary prevention, cardiovascular risk reduction, LDL cholesterol targets, treatment guidelines, drug safety, adverse events, lipid-lowering therapy
MeSH terms
Atorvastatin, Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heptanoic Acids, Humans, Male, Middle Aged, Pyrroles, Treatment Outcome, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/dc05-2415
The paper
Knopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group. (2006). Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/dc05-2415

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.